Navigation Links
VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
Date:7/30/2015

Leading regenerative veterinary medicine company, VetStem Biopharma, announced the successful completion of a field clinical study of its canine osteoarthritis stem cell product, currently under development for FDA approval. The product is being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. This product, termed AT-016, is an allogeneic adipose stem cell product for the treatment of osteoarthritis in the dog. The formal FDA Investigational New Drug Application was filed in 2011.

“I am extremely pleased to announce that our allogeneic adipose stem cell development program has reached a critical milestone with the successful completion of this significant field clinical efficacy study,” said Dr. Robert Harman (CEO and Chief Scientific Officer). The study was a double-blinded, placebo-controlled field efficacy study conducted in nine clinical sites in the US. The primary outcome variable for success showed a statistically significant improvement in the treatment versus the control dogs (P=0.05). The study final report is being prepared for FDA submission and for publication in a peer-reviewed journal. “This study is the first of its kind in the canine stem cell field and builds upon more than a decade of commitment to an evidenced-based approach to delivering regenerative medicine to our profession,” said Dr. Harman. The independent investigators in this study are leaders in surgery and pain management and will co-author the study paper with Dr. Harman.

“VetStem has demonstrated professionalism and competence in developing this innovative approach to therapy for canine osteoarthritis,” said Steven St. Peter, CEO of Aratana Therapeutics. “We chose VetStem as our partner and provider of this first-in-class stem cell product because of their leadership in the science and clinical application of veterinary regenerative medicine. Aratana is proud to be VetStem’s commercial partner and to support their development efforts,” said St. Peter.

“Everything we do today is geared toward meeting and exceeding pharmaceutical industry standards for this new treatment modality. Our colleagues deserve good science and evidence-based products and services as veterinary regenerative medicine becomes a mainstay of therapy for difficult diseases like osteoarthritis,” said Dr. Harman. VetStem will be publishing these results in a peer-reviewed journal and presenting at veterinary and human medical conferences.

About VetStem Biopharma VetStem Biopharma is a veterinarian led company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem research team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all

living creatures. The company’s stated mission being “to extend and enhance companion animal lives by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

Contacts:
Dr. Robert Harman (CEO, Chief Scientific Officer) bharman(at)vetstem.com

12860 Danielson Court, Suite B Poway, CA 92064
858-748-2004
http://www.vetstem.com

Read the full story at http://www.prweb.com/releases/2015/07/prweb12877035.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
3. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
4. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
5. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
6. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
7. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
8. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... (PRWEB) , ... September 24, ... ... be presenting their latest research in the area of high-level X-ray methods ... Dr. Pamela Smith, COO of Improved Pharma, will present “Synchrotron X-Ray Diffraction ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... has completed training and site qualification for clinical trial sites and physician investigators. ... screening of potential clinical trial participants. , Clinical trial sites are currently located ...
(Date:9/22/2019)... , ... September 20, 2019 , ... ... of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . BDNF plays a ... BDNF stimulates the growth and differentiation of new neurons in the brain involved ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a Rochester ... today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office ... class recommendations for hypertension treatment. , The patent applies to Geneticure’s first ...
Breaking Biology Technology:
(Date:9/24/2019)... ... September 24, 2019 , ... HT Medical ... porous titanium spinal implants with the expansion of its proprietary Ti3D® spinal interbody ... tripling the number of cervical and lumbar instrumentation sets available for surgical use. ...
(Date:9/17/2019)... ... 17, 2019 , ... Last week, Blackrock Microsystems, LLC, Neuro ... Medical University of Warsaw, met at the Presidential Palace of the Republic of ... system as part of an initiative called "Startups in the Palace – Cooperation," ...
(Date:9/11/2019)... ... 2019 , ... Newly released “Dream in Color” by poet ... a beautiful and thought-provoking journey through five chapters of human experience. , The ... and other times, Whittaker wrote to Srinivasan’s paintings. Together, the dynamic watermedia and ...
Breaking Biology News(10 mins):